DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Survodutide is a GLP-1/glucagon dual agonist with a strong fatty-liver (MASH) focus alongside weight loss. ~19% weight loss in Phase 2.
The glucagon-receptor arm specifically targets hepatic fat, making survodutide a leading candidate for MASH (metabolic-associated steatohepatitis) in parallel with obesity. Weekly injection.
Versus tirzepatide on weight loss: comparable-to-slightly-lower. But survodutide’s MASH data may make it the preferred agent for patients with significant fatty-liver disease, a differentiation tirzepatide does not emphasize.
Phase 3 program ongoing 2025-2027. FDA filing expected 2027, approval 2027-2028. MASH and obesity indications both in development.
Patients with obesity plus diagnosed MASH/MASLD. The dual weight-loss + liver benefit is the differentiator.
Editorial summary of investigational drugs not yet FDA-approved. Trial data and timelines change. Not medical advice; do not delay current treatment waiting for pipeline agents.